To investigate the relationship between pro‐gastrin‐releasing peptide (ProGRP) and the clinical characteristics of patients with medullary thyroid carcinoma (MTC) and the value of ProGRP in surgical treatment monitoring. Here, GRP is linked to medullary thyroid gland carcinoma.